Quantification of clonal circulating plasma cells in relapsed multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Clonal circulating plasma cells (cPCs) are established high-risk markers in newly diagnosed multiple myeloma (MM).
• The prognostic significance of cPCs in previously treated MM patients remains undetermined.

Purpose of the Study:

• To investigate the prognostic value of cPCs in patients with previously treated multiple myeloma.
• To assess the association between cPCs and disease status (relapsing vs. plateau) and survival outcomes.

Main Methods:

• Multi-parameter flow cytometry was used to evaluate cPCs in peripheral blood samples.
• A cohort of 647 previously treated MM patients was analyzed, categorizing them by disease status (actively relapsing, plateau, or complete remission).

Main Results:

• Patients with actively relapsing disease were significantly more likely to have detectable cPCs compared to those in a plateau phase (P < 0.001).
• No cPCs were detected in patients in complete remission.
• In the plateau phase, cPCs predicted significantly worse median survival (22 months vs. not reached; P = 0.004).
• Among actively relapsing patients, ≥100 cPCs predicted significantly worse survival (12 months vs. 33 months; P < 0.001).

Conclusions:

• Clonal circulating plasma cells are a valuable prognostic marker in previously treated multiple myeloma, particularly in patients with relapsing or plateau disease.
• These findings support the potential role of cPCs in developing risk-adapted treatment strategies for relapsing MM patients.